Merck SharpDohme LLC
Rescue medications(Merck Sharp & Dohme LLC)은 Endometrial Cancer 표적 ADC로, Lung Neoplasm Malignant 영역에서 개발·상용화 중입니다. 작용기전: inhibits the Wnt signaling pathway. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer.
Endometrial Cancer
Lung Neoplasm Malignant
Recruiting
CAR T-cell therapy in multiple myeloma
retroviral therapy
novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer
inhibits the Wnt signaling pathway
apoptosis, migration, and autophagy of ovarian cancer cells
biomarker associated with adverse clinical outcomes in HCC
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Merck SharpDohme LLC
Rescue medications(Merck Sharp & Dohme LLC)은 Endometrial Cancer 표적 ADC로, Lung Neoplasm Malignant 영역에서 개발·상용화 중입니다. 작용기전: inhibits the Wnt signaling pathway. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer.
Endometrial Cancer
Lung Neoplasm Malignant
Recruiting
CAR T-cell therapy in multiple myeloma
retroviral therapy
novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer
inhibits the Wnt signaling pathway
apoptosis, migration, and autophagy of ovarian cancer cells
biomarker associated with adverse clinical outcomes in HCC
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.